- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00450190
Saizen® E-Device User Trial
September 29, 2017 updated by: Merck KGaA, Darmstadt, Germany
User Trial on the Use in Common Practice of a New Electronic Auto-injector of Saizen®, the E-Device (Electronic Device), in Children Treated by Recombinant Human Growth Hormone Over a Period of 2 Months
The aim of the study is to evaluate the E-Device performances and handling on the use in common practice, by collecting the impressions of patients, nurses and the investigator on the graphic interface, the instructions manual, the E-Device training and the material itself.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients naïve to, or experienced with, Saizen® with growth disorders in registered indications (GHD, Turner's Syndrome, Chronic Renal Failure, patient born Small Gestational Age [SGA] according to the local SmPC)
- Written informed consent must be obtained from the parent(s)/legal guardian(s) at the beginning of the study. Children able to understand the trial should personally sign and date the written informed consent
Exclusion Criteria:
- Known hypersensitivity to somatropin or any of the excipients
- Epiphyseal fusion
- Active neoplasia (either newly diagnosed or recurrent)
- History of intracranial hypertension with papilledema
- Diabetes mellitus or history of significant glucose intolerance as defined by a fasting blood glucose > 116 mg/dL
- Severe congenital malformations
- Severe psychomotor retardation
- Known hepatic disease as defined by elevated liver enzymes or total bilirubin (x 2 N)
- Current congestive heart failure, untreated hypertension, serious chronic oedema of any cause
- Chronic infectious disease
- Previous or ongoing treatment with sex steroid therapy such as estrogens and testosterone
- Previous or ongoing treatment with any therapy that may directly influence growth, including GH, GHRF and long duration corticosteroids therapy
- Proliferative or preproliferative diabetic retinopathy
- Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion
- Precocious puberty
- Severe associated pathology affecting growth such as malnutrition, malabsorption or bone dysplasia
- Concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment
- Participation to any clinical study within the 30 days preceding study entry
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Saizen® E-Device
|
Saizen® (recombinant human growth hormone [r-hGH]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects' Overall Impression After Using E-Device
Time Frame: 2 Weeks
|
Subjects' overall impression after using E-Device was measured on a scale ranging from 1 to 3, where 1 = bad, 2 = good, and 3 = very good.
Number of subjects with response based on overall impression scale were presented.
|
2 Weeks
|
Usefulness and Reliability of E-Device Functions
Time Frame: 2 Weeks
|
Following functions were assessed: Display of remaining dose in cartridge, Display of last injection date and time, Automatic needle attachment, Audible and visual signals, Dose injected confirmation, Dose history, Customizable needle insertion speed, Customizable drug insertion speed, Customizable insertion depth, Teach me menu, On screen instructions, Customizable name and picture, Pre-programmed dose and Skin sensor.
Usefulness and reliability of each of the E-Device functions was measured on a scale ranging from 1 to 3, where 1 = not useful, 2 = useful, and 3 = very useful.
Number of subjects with response based on usefulness and reliability scale were presented.
|
2 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects' Feedback Immediately After Initial Training During Inclusion Visit
Time Frame: Inclusion visit (Day 1)
|
Subjects' feedback immediately after initial training on the handling and use of E-Device was assessed on scale ranging from 1 to 3, where 1 = difficult, 2 = easy, and 3 = very easy.
Subjects were provided training on the following aspects: Cartridge loading, Needle attachment, Needle detachment, Injection process, Navigation in the menu, and Handling of the device.
Number of subjects with response based on their feedback were presented.
|
Inclusion visit (Day 1)
|
Nurse/Physician's Feedback After E-Device Set up During Inclusion Visit
Time Frame: Inclusion visit (Day 1)
|
Nurse/physician's feedback was assessed for E-Device setting up and Dose programming on inclusion visit using a scale ranging from 1 to 3, where 1 = difficult, 2 = easy, and 3 = very easy.
Nurse/Physician's response for the number of subjects were presented.
|
Inclusion visit (Day 1)
|
Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs)
Time Frame: Day 1 up to Day 90
|
An Adverse Event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship.
A Serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect, AEs leading to discontinuation and AEs leading to death.
|
Day 1 up to Day 90
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Responsible, Merck Lipha Santé s.a.s., an affiliate of Merck KGaA, Darmstadt, Germany
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 28, 2006
Primary Completion (ACTUAL)
September 30, 2006
Study Completion (ACTUAL)
September 30, 2006
Study Registration Dates
First Submitted
March 21, 2007
First Submitted That Met QC Criteria
March 21, 2007
First Posted (ESTIMATE)
March 22, 2007
Study Record Updates
Last Update Posted (ACTUAL)
July 23, 2018
Last Update Submitted That Met QC Criteria
September 29, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 26443
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth Disorders
-
Northwell HealthRecruitingGrowth | Growth Disorders | Growth Failure | Growth Hormone TreatmentUnited States
-
University of CopenhagenUniversity of Aarhus; Arla FoodsCompletedGrowth Acceleration | Growth; Stunting, NutritionalDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
IpsenCompletedGrowth Hormone DisordersUnited Kingdom
-
Cornell UniversityAfrica Future FoundationCompletedMalnutrition | Growth | Stunted Growth | Feeding, ComplementaryEthiopia
-
Novo Nordisk A/SWithdrawnHealthy | Growth Disorder
-
Novo Nordisk A/SCompletedHealthy | Growth DisorderUnited States
-
IpsenCompletedGrowth Disorders | Insulin-Like Growth Factor-1 DeficiencyUnited States
-
Indonesia UniversityWyeth nutrition indonesiaCompletedGrowth; Stunting, NutritionalIndonesia
-
Danone Asia Pacific Holdings Pte, Ltd.KK Women's and Children's HospitalCompletedGrowth; Stunting, NutritionalSingapore
Clinical Trials on Saizen® E-Device
-
Merck KGaA, Darmstadt, GermanyMerck, S.L., SpainCompleted
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.A., GenevaCompletedChildren Born With Serious Intra-uterine Growth Retardation
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, GermanyCompleted
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Merck KGaA, Darmstadt, GermanyCompletedIdiopathic Short StatureKorea, Republic of
-
EMD SeronoTerminatedGrowth Hormone Deficiency (GHD)United States
-
University Hospital, LilleCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH); University...CompletedNicotine Dependence | Smoking, Tobacco | Smoking, Cigarette | Exposure to Toxic AgentUnited States
-
Merck KGaA, Darmstadt, GermanyCompletedAdult Growth Hormone DeficiencyUnited Kingdom, Germany, Australia, Sweden